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Coagulation and cancer
J.C. Murray
CRC Gray Laboratory, Endothelial Biology Group, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK.
As solid tumours rely upon the bloodstream to deliver nutri-
ents necessary for growth, it follows that interference with
that supply may compromise tumour growth. Indeed, this
suggests that manipulation ofthe blood supply may represent
a potential therapeutic approach in itself. However, any
attempt to exploit such a strategy will require a thorough
understanding of differences and similarities between normal
and tumour vasculature. Several lines of research, including
recent work from this laboratory, have suggested that one
major difference between normal and tumour-associated
blood vessels lies in the propensity of blood to clot within-
tumour vessels. While the concept of exploiting such a
difference for therapeutic reasons may be new, the observa-
tion of this abnormality is not: the association between
tumours and abnormalities of the blood coagulation system
was first recognised as long ago as 1865, when Trousseau
reported the frequent occurrence of venous thrombosis in
patients with gastric carcinoma (Trousseau, 1865). Although
great progress has since been made in unravelling the
molecular and cellular basis of this phenomenon, its
significance remains something of a mystery. In this brief
article I hope to summarise the critical clinical and experi-
mental evidence for an association between clotting abnor-
malities and cancer, discuss the mechanisms responsible, and
the potential therapeutic implications.
The coagulation system constitutes a 'cascade' of enzymes
and cofactors referred to as 'clotting factors' and designated
by Roman numerals, in order of their discovery. The ulti-
mate function of this cascade is to convert soluble circulating
fibrinogen to insoluble fibrin, and herein lies the strength and
weakness of the system: while the cascade acts as a means of
amplifying a small initiating signal, there are also numerous
points where the entire process may be either interrupted or
discrete sections bypassed. Consequently, searching for clot-
ting abnormalities requires a complex series of laboratory
tests, determining the source of the abnormality by a process
of elimination. Through the use of such tests much progress
has been made in understanding the ways in which tumours
may affect the coagulation system.
In an often quoted clinical study, Sun and colleagues
(1979) reported abnormalities of at least five standard
coagulation tests in 88 out of 108 cancer patients. The most
common abnormalities were elevation of fibrin and
fibrinogen degradation products, as well as raised circulating
levels of fibrinogen. Numerous other studies have also found
elevations in levels of specific coagulation factors, coupled
with prolongation of standard clotting times and it has been
suggested that these abnormalities are consistent with con-
tinuous low-grade intravascular coagulation and fibrinolysis,
accompanied by increased synthesis of fibrinogen and other
clotting factors. More sophisticated tests have revealed in-
creases in plasma levels of fibrinopeptide A (a cleavage pro-
duct in the conversion of fibrinogen to fibrin) in virtually all
patients with acute leukaemias or solid tumours, providing
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direct evidence for the abnormal activation of coagulation in
such patients. Disseminated intravascular coagulation (DIC),
a severe and sometimes fatal clotting abnormality charac-
terised by consumption of platelets and clotting factors, with
(paradoxically) bleeding complications, displays an unusually
high incidence in cases of promyelocytic leukaemia, but is
otherwise relatively rare.
What are the factors responsible for these abnormalities?
As early as 1954, tumour extracts had been shown to contain
procoagulation activity (Eiseman & Stefanini, 1954),
although the physiological significance of procoagulant
activity obtained by artificially disrupting cells was con-
sidered questionable. Research in the 1970s provided the first
real evidence that 'intact' viable tumour cells express pro-
coagulant factors which could be detected in conditioned
culture medium. The results of these and many other studies
can be summarised as follows
(i) Tumour procoagulant activity can take several bio-
chemical forms, acting on the coagulation pathway at
different points.
(ii) A particular tumour may activate coagulation by a
single mechanism or by multiple mechanisms.
(iii) Some mechanisms are direct, mediated through the
release of clotting factors by tumours cells, and some
indirect, mediated through other cell types i.e.
endothelial cells, monocyte/macrophages, T-cells, and
platelets.
If we consider first way in which tumours might directly
activate the coagulation pathway, two mechanisms
predominate. The first, and best understood, is the produc-
tion of tissue factor (TF, thromboplastin) by tumour cells.
TF, on association with circulating factor VII, constitutes an
extremely potent procoagulant factor which, through the
'extrinsic' coagulation pathway, directly activates factor X.
TF is a normal component of many cell types, including
endothelial cells and monocyte/macrophages, however its
biological activity is rarely expressed. Secondly, several
human and rodent tumours have been shown to express a
specific enzyme, known as cancer procoagulant (CP), which
directly activates factor X and is not factor VII-dependent
(Gordon et al., 1975); this activity is, for the most part,
absent from normal tissues. In addition to the above-
mentioned mechanisms, various other procoagulant activities
associated with tumour cells have been reported, including
thrombin-like activities, which bypass the coagulation cas-
cade entirely, directly converting fibrinogen to fibrin.
None of these mechanisms is exclusive to any particular
tumour type; more than one mechanism may apply to any
single tumour. For example Dvorak et al. (1983) showed that
many tumour cell lines and short-term tumour cell cultures
not only release tissue factor-like substances into the culture
medium, but may also enhance clotting activity by shedding
membrane vesicles which can act as a support for the
assembly of factors V and Xa into an effective catalytic unit
(prothrombinase complex) for the conversion ofprothrombin
to thrombin. This particular mechanism may be of con-
siderably more importance than previously recognised.
Finally, tumours may modify clotting activity indirectly,
through interactions with other cell types which in turn
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Figure 1 Blood coagulation pathway. The major points at which tumour cells or their products may positively influence this
pathway are indicated.
induce clotting. The ability of circulating tumour cells to
cause platelet aggregation has been reported often; this may
also lead on to coagulation. Monocytes from cancer patients
have been shown to express higher levels of TF in vitro than
those from control subjects, suggesting that monocytes from
these patients are 'preactivated'. Although the mechanism is
unknown, it may be that monocytes are stimulated by cir-
culating tumour-specific antigens or immune complexes; the
T-cell may play a role in this interaction, as it has been
shown to regulate monocyte TF production.
Very recently, evidence has come to light of enhanced
procoagulant activity resulting from tumour cell-endothelial
cell interactions. Cozzolino et al. (1988) demonstrated that
malignant cells isolated from patients with acute non-
lymphoblastic leukaemia produce interleukin 1, a cytokine
which induces TF expression on endothelial cells in vitro,
while suppressing the protein C anticoagulant pathway in the
same cells. It was suggested that such a mechanism might
account for the clotting defects seen in these patients. Peptide
factors have now been isolated from supernatants of murine
(Clauss et al., 1990) and human (Noguchi et al., 1989; Mur-
ray et al., 1990) tumour cells which increase endothelial
procoagulant activity in vitro by up-regulating TF expression.
These factors appear to be novel cytokines and their
mechanism of action is currently under investigation.
Having described some mechanisms by which tumours
may induce clotting defects, what are the consequences of
such defects for the tumour and the organism as a whole?
The presence of clotting abnormalities may facilitate meta-
static spread of tumour through the formation of tumour
emboli which can readily arrest in capillary beds. In addition
anticoagulants and agents which inhibit platelet aggregation
can, in some instances, impair metastatic spread. For these
reasons, the clotting defects associated with malignancy have
generally been considered disadvantageous to the host. And
yet little attention has been paid to the effects of coagulation
within the tumour vasculature. Whether anticoagulant therapy
has potential in terms of the primary tumour is still open to
question; however, recent studies on the mechanism of action
of tumour necrosis factor (TNFa), a cytokine produced
mainly by activated macrophages, have stimulated interest in
the possible benefit which might be obtained by deliberately
inducing coagulation within tumours.
TNFa, injected intravenously, produces dramatic tumour
shrinkage in many animal tumour models, although the
results of clinical trials have been largely disappointing.
Several clues suggest that the mechanism of action of TNFa
is largely indirect; it is frequently active against transplant-
able tumour cell lines in vivo, while displaying no cytotoxicity
toward the same cell in vitro, and it appears to promote a
host inflammatory response at the tumour site. But perhaps
more directly relevant is the effect of TNFa on the tumour
blood supply: TNFa induces the deposition of fibrin within
tumour blood vessels, which is thought to lead to vascular
occlusion and nutrient deprivation (Nawroth et al., 1988). In
vitro studies have clearly demonstrated that endothelial cells
have receptors for TNFa and that they respond to this
cytokine by increasing levels of TF on their cell surface;
interleukin-I acts on endothelial cells in a similar manner.
Although it is generally agreed that TNFx effects may be
partially mediated through the vasculature, the significance of
the induction of coagulation by TNFa is still controversial.
In one study the administration of the anticoagulant
dicoumarol prior to TNFa abrogated the growth inhibition
due to TNFa (Shimomura et al., 1988), while in another
study, coadministration of heparin with TNFa had no effect
(Watanabe et al., 1988). In a sense this argument is circular,
and assumes that the TNF-induced coagulation pathway is
sensitive to conventional anticoagulants. As has already been
indicated, tumours elaborate factors which induce pro-
coagulant activity on endothelial cells; the factor we isolated
from murine Meth-A cells has also been shown to potentiate
the effects of TNFa on endothelial cells, thus in part explain-
ing the focal nature of the TNFa effect on tumour vas-
culature (Clauss et al., 1990). It may be that the pathway
stimulated in tumour-associated endothelial cells is unusual
Table I Mechanisms by which tumours may promote coagulation
I Direct activation ofcoagulation
(i) Factor X activation Gordon etal., 1975
(ii) Tissue Factorproduction Gralnick & Abrell, 1973
(iii) Prothrombinase assembly Dvorak etal., 1983
(iv) Thrombin-like activity Strauli et al., 1980
II Indirect activation ofcoagulation
Effects oftumourderived factors on:
(i) Endothelialcells Cozzolino etal., 1988
Noguchietal., 1989
Clauss etal., 1990
(ii) Macrophages Edwards etal., 1981
(iii) Platelets Warren, 1978424 J.C. MURRAY
in terms of its sensitivity to anticoagulants, and there is some
clinical evidence to support such a notion. In one study,
patients with thromboembolic disorders as a complication of
cancer failed to normalise their fibrinopeptide-A levels in
response to intravenous heparin, in contrast to patients with
uncomplicated thromboembolic disorders (Yudelman &
Greenberg, 1982). The common observation that such patients
are refractory to conventional anticoagulant therapy (Lieber-
man et al., 1961) has led to speculation concerning the
existence in cancer patients of enzymes with thrombin-like
activity that are not inhibitable by heparin. Therefore, the
finding that anticoagulants do not entirely abrogate the anti-
tumour effect of TNFx does not exclude coagulation within
the tumour as a possible component of its activity; the ques-
tion remains open.
Flavone acetic acid (FAA), an agent which has interested
us for several years, exhibits many similarities to TNFa in
terms of both its anti-tumour activity and physiological
effects on mice. FAA causes a profound and rapid drop in
blood flow in most transplantable mouse tumours. We dem-
onstrated that this drop in blood flow was associated with a
coagulopathy characterised by lengthened clotting times and
thrombocytopenia (Murray et al., 1989). Within 15-30 min
of administration, fibrinopeptide A levels were double those
of control, indicating rapid activation of coagulation. These
changes were more profound in tumour-bearing mice than in
controls. To determine whether the endothelial cells might be
the source of the procoagulant activity, we examined the
effects of FAA on the expression of cell surface TF in vitro
and found a small but significant elevation. The expression of
TF was greatly increased, however, if the endothelial cells
were pretreated with tumour-conditioned medium. We subse-
quently showed that a peptide factor present in tumour
conditioned medium was responsible for the potentiation of
proagulant activity induced by FAA (Murray et al., 1990).
Very recent evidence has indicated that FAA induced the
synthesis de novo of TNFa and IFNa/p in vivo, and it has
been suggested that the vascular effects of FAA in vivo are
mediated indirectly through TNFa (Mahadevan et al., 1990).
However, we have demonstrated a substantial potentiation of
TNFx by FAA in vitro in terms of elevating steady-state
levels of TF mRNA, and in vivo in terms of regrowth delay
of tumours (Murray et al., 1991). Therefore it appears that
the mechanism of action of FAA may not be quite so
straightforward and that FAA may interact with, as well as
induce, cytokines such as TNFx.
To test whether the induction of coagulation by FAA is
relevant to its anti-tumour effects, we treated tumour bearing
mice with FAA and various anticoagulants which inhibit
various stages of the coagulant pathway. In no case could we
find any effect on FAA induced growth delay (Thurston et
al., in press). Therefore, for TNFa and FAA, two agents
with clear vascular components of action, the question of
relevance of coagulation to growth of the primary tumour
remains open. Is the activation of coagulation a secondary
phenomenon, or does it play a pivotal role in the sequence of
events leading to haemorrhagic necrosis of tumours? The
conclusion that coagulation is a peripheral phenomenon is
based upon experience with anticoagulants. However, as
pointed out above, this presupposes that the mechanisms
responsible for the activation of coagulation in tumours re-
spond 'normally' to anticoagulants, and this may not neces-
sarily be the case.
Although the concept of deliberately inducing localised
clotting within a solid tumour is attractive as a therapeutic
approach, we cannot yet prove that this is the mode ofaction
of existing agents. We should also consider the problem of
clot localisation; clearly there must be a fine line which
separates the production of focal coagulation within the
tumour and generalised coagulation throughout the blood-
stream, which would be disastrous. As yet, our fundamental
understanding of coagulation mechanisms and the influence
of tumour cells on those mechanisms lags behind our desire
to exploit them for therapeutic benefit and so, for the
moment, we must pursue the fundamentals.
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